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Abstract
Background: Aproximately 5–10% of cases of mental retardation in males are due to copy
number variations (CNV) on the X chromosome. Novel technologies, such as array comparative
genomic hybridization (aCGH), may help to uncover cryptic rearrangements in X-linked mental
retardation (XLMR) patients. We have constructed an X-chromosome tiling path array using
bacterial artificial chromosomes (BACs) and validated it using samples with cytogenetically defined
copy number changes. We have studied 54 patients with idiopathic mental retardation and 20
controls subjects.
Results: Known genomic aberrations were reliably detected on the array and eight novel
submicroscopic imbalances, likely causative for the mental retardation (MR) phenotype, were
detected. Putatively pathogenic rearrangements included three deletions and five duplications
(ranging between 82 kb to one Mb), all but two affecting genes previously known to be responsible
for XLMR. Additionally, we describe different CNV regions with significant different frequencies in
XLMR and control subjects (44% vs. 20%).
Conclusion: This tiling path array of the human X chromosome has proven successful for the
detection and characterization of known rearrangements and novel CNVs in XLMR patients.
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Mental Retardation (MR) is a common disorder affecting
1–3% of the general population [1]. An excess of affected
males over females has been noted among mentally
delayed patients, especially in moderate to severe MR.
This phenomenon has usually been explained by the pres-
ence of many genes responsible for MR on the X chromo-
some. X-linked MR (XLMR) is an heterogeneous
condition representing an important proportion of
patients affected by MR and can be classified either as
nonsyndromic, when mental delay is the only symptom,
or as syndromic when MR is associated with other specific
clinical features.
Copy number variations (CNVs) are defined as copy
number changes including deletions, insertions and
duplications of genomic regions that range from one kilo-
base (kb) to megabases (Mb) in size. CNVs can influence
gene expression by directly disrupting genes or by altering
gene dosage [2,3], and some are involved in specific
genetic disorders such as microdeletion and microdupli-
cation syndromes (e.g. Williams-Beuren, Smith-Magenis
or DiGeorge syndromes). Several studies report an inci-
dence of cryptic chromosomal imbalances in about 10–
25% of MR cases [4-6]. Other copy number variations are
present as polymorphisms in the general population with-
out apparent relation to disease [7-10]. Several of these
cryptic chromosomal rearrangements occur in regions
flanked by segmental duplications or low-copy repeats
and likely result from non-allelic homologous recombi-
nation between different copies of these repeats [11].
Nowadays, array-based comparative genomic hybridiza-
tion (aCGH) represents a useful and cost-effective tool for
the detection of submicroscopic copy number changes in
genetic diseases [12]. Here, we describe the development,
validation and use of a BAC derived tiling path array cov-
ering the entire euchromatic portion of the human X chro-
mosome, which has allowed the screening for copy
number changes in 54 XLMR patients.
Results
Validation of the X-chromosome BAC array
Sensitivity and specificity of the X-array to detect copy
number changes were tested with DNA from four patients
with known cytogenetic aberrations on the X chromo-
some (see material and methods). In all these individuals,
the corresponding changes in copy number were clearly
detected and confirmed by the array-CGH. A series of sex
mismatched hybridizations of controls versus controls, as
well as self-self hybridizations allowed the detection of
clones in the array that performed abnormally. Criteria for
considering problematic clones were: 1) clones with abso-
lute value of log2 ratios > 0.2 in self-self hybridizations, 2)
clones with high standard deviations (SD) (> 2 times the
deviation of deviations) in different hybridizations and 3)
clones displaying normal log2 ratios within a known
aberration. Thirty clones were considered problematic
and were excluded from further analyses.
Array CGH findings in X-linked MR patients
Fifty-two patients with unexplained XLMR and two
patients with an X-linked trait were analyzed using the til-
ing path X chromosome array. Copy number variations
were observed in 26 patients (48%) and in 8 patients
(14.8%), we identified imbalances probably causative of
the phenotype observed in the patients. An overview of
these imbalances is shown in Figure 1. Table 1 summa-
rizes the phenotype and genotype of these 8 patients.
Known genomic aberrations
In the two patients with a presumed rearrangement in the
short arm of the X chromosome (Xp11.4 and Xp11.3),
aberrations in these regions were identified by the array
CGH.
Case 1
Case one was a newborn biochemically diagnosed of OTC
deficiency. His mother had been diagnosed of OTC defi-
ciency and associated neurological impairment since
childhood. We identified a small deletion (400 kb) at
Xp11.4 both in the patient and his mother. This deletion
involved six adjacent clones (RP13-486L5, RP11-401A21.
RP11-727P7, CTD-213N1, RP11-416I6 and RP11-604A4)
and OTC, TSPAN7 (TM4SF2) and RPGR genes at Xp11.4
[13]. Deletion of the OTC and RPGR genes in the patient
was confirmed by PCR. Deletion of the TMSF4 gene was
confirmed by MLPA both in the patient and his mother
(see Additional file 1A).
Case 2
Case two was a boy with clinical suspicion of Norrie dis-
ease. He presented a severe psychomotor retardation with-
out verbal language skills, microcephaly, bilateral retinal
detachment and epilepsy. A deletion spanning 11 clones
with an estimate size of 1 Mb was identified at Xp11.3 in
the patient and his mother (see Additional file 1B). Array
results confirmed the clinical suspicion of Norrie disease.
The deletion involves NDP, MAOA, MAOB, EFHC2 genes.
In this case, epilepsy, not a common trait of Norrie dis-
ease, is probably caused by the deletion of the EFHC2
gene [14].
Patients with non-syndromic mental retardation
In 6 out of 52 patients, we identified genomic imbalances
in regions, which included at least one gene related with
MR (Table 1). Family studies supported the causal rela-
tionship with the MR phenotype observed in the index
cases and demonstrated that the imbalance was inherited
from an obligate carrier, except in case 8.Page 2 of 10
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Case three was one of four MR siblings from healthy, con-
sanguineous parents (see Additional file 1C). The major
clinical features were mild mental retardation, strabismus,
hypogenitalism, a marked synophrys or medial eyebrow
flare, a prominent nose and a broad high nasal root.
aCGH detected a deletion spanning two clones on Xq12
affecting OPHN1 gene (Figure 1C). MLPA detected a dele-
tion of exon 21 of this gene. The estimation of the altered
size was achieved by PCR which revealed a deletion
involving only exons 21 and 22. The deletion fully segre-
gates with the phenotype in the family. X-inactivation
analysis showed a skewed X-inactivation pattern in the
carrier mother (99/1) and not skewed in the carrier sister
(72/28).
Case 4
Case 4 was a boy affected by mild MR, dyslexia and mild
dysmorphic features. A duplication of approximately 1
Mb was detected at Xp22.12 (Figure 1D), affecting four
genes (CXorf23, MAP7D2, EIF1AX and RPS6KA3). MLPA
study detected duplication of RPS6KA3 in the patient, one
sister, mother and affected uncles (see Additional file 1D).
X-inactivation studies showed a random X-inactivation
pattern in the mother (41/59).
Array CGH profiles for XLMR patients with relevant CNVsFigure 1
Array CGH profiles for XLMR patients with relevant CNVs. Each dot represents the mean log2 transformed and Lowess nor-
malized test over reference intensity ratio (y-axis), which is derived from four independent replicate spots on the array, in a 
replicate dye swap experiment. The Mb position of the clones on the X chromosome is displayed in the x-axis, ordered from 
p-telomere to q-telomere on the basis of physical mapping positions, according to the hg17 assembly of the UCSC genome 
browser [34]. (A) 400-kb deletion at Xp11.4 (37.9–38.8 Mb) in patient 1. (B) Deletion spanning a region of 1 Mb (43.01–43.98 
Mb) in Xp11.3 in patient 2. (C) Deletion of two clones in Xq12 spanning 82 kb (67.10–67.18 Mb) in patient 3. (D) 800-kb dupli-
cation at Xp22.12 (19.82–20.65 Mb) in patient 4. (E) Duplication of 700 kb at Xq28 (152.4–153.1 Mb) in patient 5. (F) Duplica-
tion of 250 kb at Xq28 (153.2–153.5 Mb) in patient 6. (G) Duplication of 400 kb at Xp11.22 (53.53–53.94 Mb) in patient 7. (H) 
Duplication of 180 kb at Xq12 (62.07–62.26 Mb) in patient 8.Page 3 of 10
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Table 1: Patients with mental retardation and imbalances detected with the X-chromosome tiling path BAC array not identified in control samples
Case Region Gain/loss Size kb Origin Phenotype Altered clones Affected genes Confirmatory studies
Known
1 Xp11.4 Loss 400 Inherited OTC deficiency, neurological 
deterioration
RP13-486L5, RP11-401A21, RP11-727P7, 
CTD-2135N1, RP11-416I6, RP11-604A4
RPGR, OTC, TMSF4 
(TSPAN7), SRPX
Arranz et al., 2007
2 Xp11.3 Loss 1Mb Inherited Norrie disease, severe 
psychomotor retardation, 
epilepsy, microcephaly,
RP11-558I17, RP11-561O22, RP11-643D7, 
RP11-455O7, RP11-72J3, RP11-291H16, 
RP11-355O20, RP11-11B9, RP11-634A3, 
RP11-110B2, RP11-605I23
NDP, MAOA, MAOB, EFHC2 Rodriguez-Revenga et al., 2007
Causal
3 Xq12 Loss 82 Inherited Severe MR, strabismus, 
cerebellar hypoplasia, Dandy-
Walker malformation, 
prominent chin, high nasal root
RP11-586C9, RP11-466E18 OPHN1 MLPA PCR
4 Xp22.12 Gain 800 Inherited Mild MR, Robust built, dyslexia, 
facial dysmorphism
RP11-191B9, RP11-393H10, RP11-382L18, 
RP11-254G9, RP11-367L17, RP11-203E14, 
RP11-703P16, RP11-48D14, RP11-712B24, 
RP11-158M19
RPS6KA3, CXorf23, EIF1AX MLPA
5 Xq28 Gain 700 Inherited Severe MR, psychomotor 
retardation, hypotonia,
RP11-54I20, RP11-437K1, RP11-314B3, 
RP11-398P14, RP11-846A22, RP11-617G6, 
RP11-485N14, RP11-119A22, RP11-333O6, 
RP11-330B2, CTD-2238E23
SLC6A8, PLXNB3, L1CAM, 
MECP2, IRAK1, ARHGAP4, 
OPN1MW, CXorf2, TKTL1, 
PDZK4, ABCD1, PNCK, 
DUSP9, FAM58A, ATP2B3
MLPA
6 Xq28 Gain 250 Inherited Moderate MR, facial 
dysmorphism, microcephaly,
RP11-666B23, RP11-316P8, CTD-2511C7, 
CTD-2242O14, RP11-696D6, RP11-103M23
GDI1, FLNA EMD, TAZ, 
TKTL1, RPL10, DNASE1L1
MLPA RT-PCR
Causal?
7 Xp11.22 Gain 420 Inherited Moderate MR RP11-390E18, RP11-585D6, RP11-555J12, 
RP11-272G22, RP13-444K19
HUWE1, PHF8? MLPA
8 Xq12 Gain 350 ND Moderate MR RP11-414C19, RP13-547B18, RP11-655E9, 
RP11-715J23
EDA2R MLPA
ND, not determined; in bold are represented the genes related to MR.
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This boy was born to healthy nonrelated parents at term.
His psychomotor development was delayed with severe
MR, generalized hypotonia, limited walking and speech
delay. He has a family history of MR (affected relatives not
studied)(see Additional file 1E). He presented some mild
facial dysmorphisms such as narrow forehead, thin nose,
small mouth and marked dark rings under the eyes. aCGH
showed a duplication of at least 700 kb involving 15 genes
at Xq28 (Figure 1E), including SCL6A8 and MECP2 genes.
Specific MLPA for this region confirmed duplication of
MECP2, L1CAM and IRAK1 genes in the patient and his
mother.
Case 6
This boy was diagnosed of mild MR with an IQ of 58. He
was born at 8 months from non-consanguineous parents
after a pregnancy affected by acute pancreatitis. He pre-
sented neonatal seizures and cyanotic crisis. He acquired
sedestation at 6 months, deambulation at 14 months and
speech at 15 months. He showed psychomotor delay and
learning disabilities, microcephaly, hyperkinesias and
other mild dysmorphic features such as medial eyebrow
flare and deep palate. A duplication spaning 6 clones with
an estimate size of 250 kb was identified at Xq28 (Figure
1F). MLPA confirmed duplication of GDI1, FLNA and
EMD genes and discarded any alteration in the MECP2
gene in the patient, two affected relatives and two carrier
women (see Additional File 1F). RT-PCR studies revealed
a significantly higher GDI1 expression in the patient and
his affected uncle (from 2.8 to 5 fold compared to four
male controls; (SD = 0.19 Ct controls; SD = 0.09 Ct
patient; SD = 0.25 Ct affected uncle). The carrier mother
showed a complete skewed X-inactivation (100/0) inacti-
vating the X-chromosome inherited by the patient.
Case 7
Case 7 was a boy affected by moderate MR, and minor
dysmorphic features. aCGH detected a duplication of
approximately 420 kb spanning the HUWE1 gene and
probably the PHF8 gene at Xp11.22 (Figure 1G). The
development of MLPA custom probes for HUWE1 and
PHF8 allowed confirmation of the duplication of HUWE1
gene both in the patient and his affected brother (see
Additional file 1G) and discard implication of PHF8 gene
in the duplication. His mother was carrier of the duplica-
tion. X-inactivation pattern was skewed in the mother
(90/10) and not skewed in the aunt (77/23). The screen-
ing of 75 normal male controls did not detect this CNV in
any of them.
Case 8
Case 8 was a boy with moderate mental retardation and
minor facial dysmorfisms. He has a family history of MR
although no family members were available for study (see
Additional File 1H). A duplication of approximately
350kb, involving four clones on Xq12 was identified by
aCGH (Figure 1H). The duplication spans the EDA2R
gene that encodes a receptor of the tumor necrosis factor
receptor family. MLPA screening with custom probes for
EDA2R gene confirmed the duplication in the patient and
discarded it in 75 male controls.
Some other variations identified in XLMR patients corre-
spond to previously reported CNVs present in the refer-
ence database of genomic variants [15]. The most
common ones were deletions and reciprocal duplications
in the Xq28 and Xq26.3 regions of an average size of 200
kb and 140 kb, respectively. The proportion of patients
carrying CNVs was double than that of controls (44% vs.
20%). Further description of the identified CNVs is pro-
vided in Table 2. In general XLMR patients presented
more changes and duplications were more common in
XLMR patients than in controls (Table 3).
Discussion
The applicability of the array-based comparative genomic
hybridization technology to detect copy number changes
in mentally delayed patients has been described in a
number of previous reports. An incidence of cryptic
Table 2: X-chromosome CNVRs detected in patients and controls using the X-chromosome tiling path BAC array.
Region Controls 
(20)
Cases 
(54)
Start Clone End Clone Size kb Gain/Loss OMIM Genes within CNVs
Xp22.33 - 1 2497952 RP11-325D5 2773932 RP11-457M7 278 Gain CD99, XG, GYG2
Xp22.31 1 - 9304013 RP11-951B16 9510840 RP11-29K8 207 Gain TBL1X
Xp21.2 1 - 30597301 RP11-710J8 30681589 RP11-642K22 84 Loss TAB3
Xp11.23 - 1/1 47732169 RP11-423H3 47806532 RP11-38O23 74 Loss/Gain SSX5, SSX6, LOC389852
Xq26.3 -/1 3/4 134591734 CTD-2225C20 134733742 RP11-111C16 142 Loss/Gain SAGE1, MGC88118, 
MGC27005
Xq28* 1/- 7/7 152963046 CTD-2149G5 153072850 RP11-330B2 110-315 Loss/Gain OPN1LW, OPN1MW
Xq28 1 - 151551673 RP11-793M20 151886266 CTD-2515E20 335 Loss MAGEA6, MAGEA12, 
MAGEA2B, MAGEA2, 
MAGEA2B, CSAG2, 
MAGEA3Page 5 of 10
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BMC Genomics 2007, 8:443 http://www.biomedcentral.com/1471-2164/8/443imbalances in about 10–25% of the cases has been
reported [4,5,16-18]. With the aim of identifying novel
aberrations involved in the cognitive impairment in
XLMR patients, we have developed a tiling path X chro-
mosome array for CGH with a 100 kb resolution. Clini-
cally relevant imbalances were identified in 8 cases
(14,8%) with genomic sizes ranging between 100 kb and
900 kb. In all these cases we have identified genes related
to MR that could be responsible for the phenotype in
these patients (Table 1). In cases 1 and 2, array CGH sup-
ported the previous clinical suspicion and helped to
roughly delineate the location of breakpoints for the dif-
ferent aberrations. In case 3, the identification of an 82 kb
deletion, affecting exons 21 and 22 of the OPHN1 gene at
Xq12, demonstrated the usefulness and accuracy of array
CGH to detect small copy number changes. In cases 4, 5
and 6 we identified duplication of RPS6KA3, MECP2, and
GDI1 genes, respectively, all of them implicated in mental
retardation and neurological disease. Mutations in
RPS6KA3 are responsible for the Coffin-Lowry Syndrome
and GDI1 has been related to nonsyndromic MR forms.
As previously pointed out [19] we propose that the copy
number alteration of dosage sensitive genes RPS6KA3 and
GDI1 may be the major cause for the mental retardation
in cases 4 and 6, respectively. In fact, case 6 and related
family members carrying the duplication at Xq28 pre-
sented higher GDI1 mRNA levels than controls. As far as
we are aware, there is only other report describing dupli-
cations of RPS6KA3 and GDI1 genes causing MR. Froyen
et al.,(2007) described a boy with psychomotor delay with
a small duplication of 0.3Mb in size involving the XLMR
genes FLNA and GDI1, among others [20]. In the same
work, they also detected a duplication of 21 Mb involving
known MRX genes such as RPS6KA3, CDKL5 and
NLGN4X in a patient affected by severe psychomotor
delay. The detection in our series of two cases with smaller
duplications involving GDI1 and RPS6KA3 genes rein-
forces the idea that increased gene dosage of these genes
may be related to abnormal cognitive impairment.
In cases 7 and 8 we detected duplications of regions in
which no genes involved in MR have been described. In
case 7, the duplication at Xp11.22 was proximal but close
to the MR related PHF8 gene [21]. MLPA only confirmed
duplication of HUWE1 gene and although PHF8 is not
implicated in the duplication, it might be somehow influ-
enced by this CNV. In case 8, the duplication at Xq12 was
confirmed by MLPA of EDA2R gene, which encodes a
tumor necrosis factor receptor. Although the imbalance
was confirmed by other molecular method, no DNA from
the parents was available for genotyping and we could not
establish the causativeness of the aberration in the
observed phenotype. Nevertheless, duplications of
HUWE1 and EDA2R have not been detected upon screen-
ing 75 male controls neither have ever been reported as
genomic polymorphisms, suggesting that these changes
are not very common in the general population. Never-
theless, further studies are needed in order to clarify their
role in MR.
It has been shown that in several X-linked disorders, the
X-inactivation process evidences a bias in mothers of
affected individuals [22]. We have investigated the X-inac-
tivation pattern in six female carriers. Fifty per cent of
them showed a skewed X-inactivation of the chromosome
carrying the mutant allele, which is in agreement with the
literature [22]. However we have to bear in mind that this
inactivation pattern has been observed in blood samples
and we do not know what is happening in other tissues.
Until now among mentally retarded patients, deletions
were the most commonly genomic aberrations identified.
Recently, the use of array technologies has led to the
detection of new duplications in mentally retarded
patients and the description of new syndromes, i.e.
MECP2 duplication syndrome [23]. The identification of
new cases harboring duplications in these genes should be
of help in order to elucidate their potential involvement
in XLMR.
The number of described CNVs in human genome is
exponentially increasing due to the high number of
genome wide analyses. Nowadays there are reported more
than 3500 CNVs, 110 on the X-chromosome [15]. We
described here seven different CNV regions in the X-chro-
mosome (Table 2). All these CNV regions overlap with
others previously identified [10,24,25], and all are associ-
ated with segmental duplications. One of the most com-
mon CNV both in XLMR patients and in control subjects
is at Xq28, at approximately two Mb from the telomere
and associated to known segmental duplications. CNV
regions and segmental duplications are not uniformly dis-
tributed throughout the genome, being significantly over-
represented in number within two Mb of telomeres and
centromeres [26]. This Xq28 polymorphic region encom-
passes the opsin cluster, a family of genes involved in
color perception. It has been previously reported that
Table 3: Summary of changes detected both in controls and 
XLMR patients
Controls (20) Patients (54)
Samples with CNVs 20% (4/20) 48% (26/54)
Total of CNVs 5 32
Dups 20% (1/5) 56,2% (18/32)
Dels 80% (4/5) 43,7% (14/32)
CNVs/sample 1CNV 75% (3/4) 71,9% (23/32)
2CNVs 25% (1/4) 28,1% (9/32)
Size 100–400kb 100–900KbPage 6 of 10
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BMC Genomics 2007, 8:443 http://www.biomedcentral.com/1471-2164/8/443many genes involved in the senses such as olfactory recep-
tors and opsins (cone pigments) associate with CNVs
[10,27]. The second most common CNV in XLMR patients
is at Xq26.3. This region is polymorphic in the general
population [10,25,28] and it contains several cancer-
related genes such as SAGE and MAGE tumor antigen
families. Curiously, CNVs are more common in XLMR
patients than in controls; i.e. 26% of patients were poly-
morphic for the Xq28 region vs. 5% of controls. Further-
more, the percentage of CNVs is statistically higher in
XLMR than in controls (proportion test Z = 2,51, p =
0,012; Fisher's exact test: P-Value = 0,035). Also the aver-
age size is higher of CNVs seems to be higher in patients
than in controls (Table 3). We still do not know the signif-
icance of some of these CNVs, i.e. they can influence
expression of other genes. Further characterization of
these variable regions, including quantitative analyses,
opens a new field of study that should assist to understand
the role of this genomic variation in mental retardation.
Conclusion
The X chromosome aCGH presented here has been
proven successful for the detection of novel CNVs and
characterization of known rearrangements in XLMR
patients. Even more we have detected some polymorphic
CNV that seem to be more frequent in XLMR than in con-
trols. Further characterization of these variable regions,
including quantitative analyses, opens a new field of study
that should assist to understand the role of this genomic
variation in MR.
Methods
Patient and control samples
We studied a total of 54 unrelated patients with mental
retardation: 52 MR patients belonging to families compat-
ible with an X-linked inherited MR and two patients with
suspicion of an X chromosome deletion due to their clin-
ical manifestations (OTC deficiency and Norrie disease).
All XLMR patients displayed normal karyotype, and CGG-
expansions of the FMR1 gene were ruled out. We also
studied four samples with cytogenetically visible copy
number aberrations validated by molecular cytogenetic
techniques (46, XX, dupXq22-q26; 46, XX, dupXq28; 46,
XX, delXq27-qter; 46, XX, dupXp11-p21) and a series of
20 control males.
This study has been approval by the ethic committee of
the Hospital Clinic of Barcelona. All the subjects provided
written informed consent for the use of their phenotypic
and genetic data.
Construction of the tiling-path X chromosome CGH array
The X chromosome-specific tiling path array consists of
about 1,600 genomic BAC clones derived from the
human X chromosome plus 3 Drosophila negative con-
trol clones. The clone set used to produce this array was
mainly derived from the 32 K human BAC library from
the Children Hospital Oakland Research Institute [29].
Gaps were covered using BACs from other libraries
(mainly RP11). Slides contained quadruplicates of the
1,600 clones providing an average density of at least one
clone per 100 kb along the entire euchromatic portion of
the X chromosome. The production of the X-array, probe
preparation, and hybridization on the array were per-
formed in the Microarray Unit of the Center for Genomic
Regulation (CRG, Barcelona, Spain). BAC DNA was iso-
lated from 1.5 ml bacterial cultures using the Montage
BAC96 Miniprep kit following manufacturer's instruc-
tions (Millipore, Billerica, MA). DNA amplification by
DOP-PCR was done as previously described [30]. PCR
products were purified using the Montage PCR96 Plates kit
(Millipore, Billerica, MA) and quantified using the
PicoGreen dsDNA Quantification kit (Invitrogen, Life
technologies, Carlsbad, CA). Purified products were dried,
dissolved at 400 ng/µl in 50% DMSO and spotted in
quadruplicate using a VersArray ChipWriter™ Pro System
(Bio-Rad).
Sample hybridization
Hybridization was performed as previously described
[31]. For each hybridization, 400 ng of test and control
DNA were labeled by random priming using the BioPrime
Array CGH Genomic Labeling System (Invitrogen, Life
technologies, Carlsbad, CA). Reversed-dye labeling of the
samples was always used to minimize the effect of dye-
specific artifacts. Each patient was hybridized against a
sex-matched pool of 50 healthy controls. Arrays were
scanned using an Agilent G2565BA MicroArrayScanner
System (Agilent Inc., Palo Alto, CA) and the acquired
images were analyzed using GenePix Pro 6.0 software
(Axon, Molecular Devices) using the irregular feature find-
ing option. Extracted raw data was filtered and Lowess
normalized using Bacanal (Lozano et al., unpublished),
an in-house developed suite for microarrays analysis
linked to a management system.
On top of an Apache server and an Oracle database, a
combination of different R packages process the raw data
obtained from GenePix, performs a quality control of the
signals, performs a loess normalisation of spot signals
(using LIMMA package) taking into account spot quality
control and background intensities and tries to identify
copy number variable regions using circular binary seg-
mentation (using the DNAcopy R package). SD of all X-
chromosome clones was calculated for each hybridization
experiment. Genomic imbalances were determined based
on log2 of the Cy5/Cy3 ratios of the average of the four
replicates, and regions were considered as duplicated or
deleted when at least two consecutive clones exceeded the
± 0.2 range.Page 7 of 10
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Putative copy number aberrations were confirmed by
other molecular techniques such as Multiplex Ligation-
dependent Probe Amplification (MLPA), quantitative PCR
(qPCR) and/or PCR
Multiplex Ligation Probe Amplification
All 54 samples were included in a parallel MLPA screening
[32] in which we used a commercial specific probe mix-
ture with 43 probes for 14 known genes responsible for X-
linked MR (Salsa P106, MRC-Holland, Amsterdam, The
Netherlands). Additionally for MECP2 gene we used a
specific kit for Rett syndrome that includes probes for
MECP2, L1CAM and IRAK1 genes (Salsa P015C, MRC-
Holland, Amsterdam, The Netherlands). The assays were
performed following manufacturer's recommendations
(MRC-Holland, Amsterdam, The Netherlands). Specific
MLPA probes were designed for HUWEI1, PHF8, EMD,
EDA2R and FLNA genes for screening of 75 male controls
(see Additional file 2).
PCR
PCR was always performed for confirmation of our array-
CGH data when losses were detected. Primers for OPHN1
gene (case 3) were designed with the Primer3 software
(primer3 V0.3.0) (see Additional file 3).
Quantitative RT-PCR
Expression of GDI1 gene was analyzed by real time RT-
PCR using TaqMan probes (ref. Hs00181741_m1,
Applied Biosystems, CA, USA). Total RNA of the patient
and other affected males in the family was extracted from
whole blood. Relative quantification was performed
against a control amplicon of the GUSB mRNA following
manufacturer instructions (Applied Biosystems, CA,
USA).
X-inactivation
Androgen-receptor gene methylation assay to assess the
methylation status was performed over lymphocyte
genomic DNA of female carriers, as previously described
[33]. Results are presented as the percentages of inactiva-
tion of both alleles. Skewed alleles were considered when
the inactivation percentage was over 80%.
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